The company stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.

THIO has gained its generic name and preclinical data on a different form of the cancer drug suggests it could improve ...

This comprehensive review analyzes cutting-edge tools and technologies in modern pharmaceutical research, focusing on ...

Cargo Therapeutics, a Bay Area biotech company, announced in a filing Tuesday that it is discontinuing its drug development ...

Elevation Oncology discontinues EO-3021 for gastric and gastroesophageal junction cancers after phase 1 trial shows ...

Experts say the approach could also save millions of pounds by cutting projects or clinical trials that would otherwise fail.

Pathology is a field that seems ripe for assistance from recent advances in artificial intelligence. Beck’s company is one of ...

"The clinical promise of pocenbrodib, our potential best-in-class CBP/p300 inhibitor, lies not only in its remarkable efficacy in resistant prostate cancer models, but also in our sophisticated ...

Shares of Elevation Oncology ELEV plunged more than 40% yesterday after reporting disappointing data from a phase I study on ...

Q Genetics secured investment from K-Ground Partners' IP Fund, giving impetus to its new drug development endeavors. Subsequent to the completion of its Phase 1 trial, t ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

During a health-focused event in New York on Tuesday, Google announced the development of a new collection of “open” AI ...